



#RESEARCHNEVERSTOPS

TUESDAY 8<sup>th</sup> MAY, BIO<sup>M</sup> BIOTECH CLUSTER DEVELOPMENT GMBH

# DRUG DISCOVERY & DEVELOPMENT COLLABORATION FORUM

*IZB West II, Bio<sup>M</sup> Conference room, 3<sup>rd</sup> Floor  
Am Klopferspitz 19a, 82152 Martinsried, Germany*

Evotec's clients cover the entire spectrum from virtual start-ups to pharma and we have seen a significant change in the operational model of our partners in the last 20 years. Pharma companies, Biotech and NewCos are increasingly relying on external collaborations to achieve gains in efficiency. In addition not-for-profit organisations and academic institutions are also engaging in supporting industry-standard drug discovery efforts. This has allowed us to invest into building a unit capable of providing the specialised biology capabilities & expertise required to routinely discover and develop superior drug candidates.

Through this session, we would like to share our insights on how our flexible business models and a connected, collaborative and agile culture has helped us successfully deliver multiple projects for our partners.

## AGENDA

- ▶ 9:30 - 10:00 am Coffee & Registration
- ▶ 10:00 - 11:00 am Hit Identification – How to start a drug discovery programme right
- ▶ 11:00 - 12:00 pm Successfully delivering Medicinal Chemistry Programmes
- ▶ 12:00 - 13:00 pm Lunch & networking
- ▶ 13:00 - 14:00 pm Creating value – How to convert academic ideas into drug discovery programmes
- ▶ 14:00 - 15:00 pm IND and beyond – Accelerating development for entry into the clinic
- ▶ 15:00 - 17:00 pm Coffee & networking

*Register via the following link:  
[www.bio-m.org/drug-discovery](http://www.bio-m.org/drug-discovery)*



## HOSTS

### **Hermann Josef Kaiser**

*Director, Business development*



### **Andreas Berghammer**

*Head of Strategic management,  
Bio<sup>M</sup>*



## SPEAKERS

### **Dirk Ullmann**

*Global Head of Drug Discovery  
Services*



### **Steve Bromidge**

*EVP Discovery Chemistry*



### **Thomas Hanke, Ph. D.**

*Executive Vice President,  
Head of Academic Partnerships*



### **Roberto Dorigatti**

*SVP Integrated Development  
Programmes*

## ABOUT

**Evotec** is a drug-discovery & development solutions company offering the life sciences industry a variety of ways to access drug discovery innovation & development expertise in a time efficient manner, as stand-alone or integrated projects and have the confidence that through creative deal making and high quality alliance and project management, their programmes are in safe hands.

The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in multiple areas including neuroscience, pain, fibrosis, respiratory diseases, metabolic diseases, oncology, inflammation and infectious diseases.

**Bio<sup>M</sup>** is the non-profit networking organisation for biotechnology in Munich and Bavaria. The cluster management brings together regional SMEs, industry partners, investors and other relevant stakeholders, either national or international.

The experienced team offers comprehensive support for founders and founders "to be" in medical biotechnology, including individual consulting and advice about funding and financing opportunities. There are specialised coaching, training, and mentoring services as well as networking events for the start-up scene, constituting a "virtual biotech incubator" for projects in the early stages of company foundation.

For biotech entrepreneurs and their employees, Bio<sup>M</sup> organizes seminars, trainings and networking events. Discover more at [www.bio-m.org](http://www.bio-m.org)

Dr. Dirk Ullmann has more than 20 years experience in drug discovery research and collaborative business. In his role as Global Head of Drug Discovery Services he oversees the operational business together with core responsibility for the scientific strategy of the company in Hit Identification, Structure-based Drug Discovery, Protein and Cellular Sciences, ADME-Tox and DMPK, Compound Management and Proteomics. Before joining Evotec he held a position as Chief Scientific Officer at Proteros, Munich after initial 11 years with Evotec before. Dirk Ullmann obtained his PhD in Chemistry and Biochemistry from the University of Leipzig, Germany on protease-catalyzed peptide synthesis and did his post-doctoral training on protein engineering at Brandeis University, Waltham MA, (USA).

Dr. Steve Bromidge has more than 20 years' experience in drug discovery research and has been associated with the progression of multiple development and clinical candidates. In his role as Global Head of Discovery Chemistry he oversees the operational business together with core responsibility for the effective execution of high quality medicinal chemistry strategies. Before joining Evotec 7 years ago, he held various positions at GSK and its legacy companies in the UK and Italy. Steve obtained his first degree in Chemistry and PhD in Synthetic Organic Chemistry from the University of Leeds (UK).

Since December 2016, Thomas is overseeing strategic academic partnerships at Evotec including LAB282 in Oxford. Since November 2013, Thomas has been responsible for Evotec's R&D projects in inflammation and immuno-oncology.

From 2007 to 2013, Thomas was Sourcing Director at Novo Nordisk and responsible for partnering opportunities within haemophilia, autoimmune/inflammatory diseases, growth disorders and protein technologies.

Previously, Thomas was co-founder and CSO at TeGenero, where he developed first-in-class immunomodulatory monoclonal antibodies (2002–2007).

During his academic days, Thomas was group leader at the University of Würzburg, following a PostDoc at the University of California at Berkeley. Thomas received his Ph.D. in Biology 1995. He is (co-) author of numerous scientific papers in peer-reviewed journals and patent applications.

Roberto has more than 30 years' industry experience in drug development from pharmacological target assessment and lead optimization to market approval. prior to joining Evotec Roberto worked at Aptuit & GSK. He has extensive knowledge and expertise in the design and execution of development project plans, including problem-solving investigative studies, management of project teams and interaction with regulatory agencies.

He has been deeply involved in the preclinical development of drugs in multiple disease areas as senior discipline leader and as project team leader, as well as leading a number of projects both in the discovery phase and full development up to Phase I. He has experience in writing and reviewing relevant sections of regulatory submissions including Investigator's Brochure, IND, CTD, IMPD, and registration dossiers, as well as knowledge of International and ICH guidance documents and regulatory requirements.